Congresses
Madrid ,  Spain 29 August - 1 September 2025

European Society of Cardiology Congress (ESC 2025)

Presentation schedule and materials
Friday, 29 August 2025
08:35  - 08:45
CEST
SHORT ORAL PRESENTATION
Effects of semaglutide in patients with type 2 diabetes and peripheral artery disease: An analysis of the STRIDE trial stratified by disease severity and age
Joakim Nordanstig1; Ecenur G. Arslan2; Andrei-Mircea Catarig2; Kim Houlind3,4; Bernhard Ludvik5; Neda Rasouli6; Harald Sourij7; Sebastian Thomas8; Subodh Verma9; Marc P. Bonaca10
MATERIALS AVAILABLE
stride_by_padandage_oral_presentation
Slide
14:30  - 15:30
CEST
ORAL PRESENTATION
Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial
Rodica Pop-Busui1,2; Søren Rasmussen3; John E. Deanfield4; John B. Buse5; Nikolaus Marx6; Sharon L. Mulvagh7; Silvio E. Inzucchi8; Johannes F. E. Mann9; Scott S. Emerson10; Neil R. Poulter11; Mads D. M. Engelmann3; G. Kees Hovingh3; Katrine Bayer Tanggaard3; Andreas L. Birkenfeld12,13,14; Kim A. Connelly15; Martin Haluzik16; Matthew A. Cavender5; Monika Kellerer17; Pardeep S. Jhund18; Søren Gregersen19,20; Olav Wendelboe Nielsen3; Carolyn S. P. Lam21,22; Darren K. McGuire23; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
revised_esc_2025_soul_hf_oral_final_with_cois_slide
Slide
Saturday, 30 August 2025
08:15  - 09:45
CEST
ORAL PRESENTATION
Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Sharon L. Mulvagh1; Silvio E. Inzucchi2; Nikolaus Marx3; Neil Poulter4; John E. Deanfield5; Rodica Pop-Busui6; Scott Emerson7; Johannes F. E. Mann8; Mads D. Engelmann9; G. Kees Hovingh9; Kabirdev Mandavya10; Zaklina Davicevic-Elez9; Ole Kleist Jeppesen9; Alberto Lorenzatti11; Aytekin Oguz12; Boris Mankovsky13; Chaicharn Deerochanawong14; Juan Jose Gorgojo Martinez15; Linong Ji16; Stephen C. Bain17; Darren K. McGuire18; John B. Buse19; on behalf of the SOUL Study Group
MATERIALS AVAILABLE
esc25_mulvagh_impact_of_oral_sema_cv_risk_oral
Slide
10:00  - 10:45
CEST
Symposium
Unravelling cardiovascular inflammation in ASCVD: From evidence to guidance
Roxana Mehran ;  Paul M Ridker ;  Christian Matter ;  Felicita Andreotti
MATERIALS AVAILABLE
esc_ascvd_matter_scihub_teaser
Teaser Video
esc_25_ascvd_recording
Full Recording
Sunday, 31 August 2025
09:00  - 09:15
CEST
Abstract #7389
ORAL PRESENTATION
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Lauren Wilson1; Zhenxiang Zhao1; Victoria Divino1; Matthew Bassan1; Briain O Hartaigh1; Kerem Ozer1
MATERIALS AVAILABLE
esc_2025_steer_presentation_lum-kop-01222_final
Slide
09:30  - 09:45
CEST
ORAL PRESENTATION
Sex Specific Differences in Peripheral Artery Disease and Semaglutide Efficacy in the STRIDE Trial
Subodh Verma1; Andrei-Mircea Catarig2; Kim Houlind3,4; Bernhard Ludvik5; Joakim Nordanstig6; Neda Rasouli7; Harald Sourij8; Sebastian Thomas9; Sidse K. Nørgaard2; Marc P. Bonaca10
MATERIALS AVAILABLE
stride_by_sex_esc25_oral_presentation_final_presentation
Slide
10:00  - 10:45
CEST
Symposium
GLP-1RAs in obesity-related HFpEF: A new era in treatment
Carolyn Lam ;  Maja Cikes ;  Justin Ezekowitz
MATERIALS AVAILABLE
esc_hf_2025_chair_teaser
Teaser Video
esc_2025_hf_recording
Full Recording
12:30  - 13:30
CEST
Symposium
A change of heart – why cardiologists can’t ignore semaglutide
Tina Vilsbøll ;  Mark Petrie ;  Nikolaus Marx ;  Mikael Rydén
MATERIALS AVAILABLE
esc_glp1ra_vilsboll_teaser_v4
Teaser Video
esc_25_glp1_recording
Full Recording
esc_glp-1ra_symposium_summary_infographic-1
Infographic
esc_glp-1ra_symposium_summary_infographic-2
Infographic
esc_glp-1ra_symposium_summary_infographic-3
Infographic
esc_glp-1ra_symposium_summary_infographic-4
Infographic
esc_glp-1ra_symposium_summary_infographic-5
Infographic
Monday, 01 September 2025
13:15  - 14:00
CEST
3591
POSTER
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
Michael Shechter1; Vanita R. Aroda2; G. Kees Hovingh3; A. Michael Lincoff4; Ildiko Lingvay5; Ana Laura De Souza Almeida Matos3; Nina M. Harder-Lauridsen3; Derrick Musinga3; John W. Ostrominski6; Benjamin M. Scirica7; Peter E. Weeke3; Jorge Plutzky6
MATERIALS AVAILABLE
esc25_select_lipids_on_mace_poster_slides_final_27aug25
Slide
esc25_select_lipids_poster_final_31jul25
Poster
13:15  - 14:00
CEST
POSTER
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease in high-risk type 2 diabetes​
Matthew A Cavender1; Nikolaus Marx2; Sharon L Mulvagh3; John E Deanfield4; John B Buse1; Silvio E Inzucchi5; Rodica Pop‑Busui6; Johannes FE Mann7,8; Scott S Emerson9; Neil R Poulter10; Mads DM Engelmann11; G Kees Hovingh11; Alberto Lorenzatti12; Aytekin Oguz13; Jose F Kerr Saraiva14; Robinson Sanchez Garcia15; Søren Tetens Hoff11; Derrick Musinga11; Ecenur Guder Arslan11; Darren K McGuire16; on behalf of the SOUL study group
MATERIALS AVAILABLE
esc_2025_cavender_soul_polyvascular_disease_eposter
Poster
14:30  - 14:40
CEST
3127​
ORAL PRESENTATION
Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial
Jorge Plutzky1; Helen M. Colhoun2; John Deanfield3; G. Kees Hovingh4; Ildiko Lingvay5; Michael Maeng6; Søren Rasmussen4; Donna H. Ryan7; Signe Stensen4; Subodh Verma8; Peter E. Weeke4; A. Michael Lincoff9 
MATERIALS AVAILABLE
plutzky_esc25_select_afib_presentation_final_present_v2_sh
Slide
Keywords
Cardiovascular Disease
ESC